Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.

Journal Article (Journal Article)

Background

Majority of chondrosarcomas are associated with a number of genetic alterations, including somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, but the downstream effects of these mutated enzymes on cellular metabolism and tumor energetics are unknown. As IDH mutations are likely to be involved in malignant transformation of chondrosarcomas, we aimed to exploit metabolomic changes in IDH mutant and non-mutant chondrosarcomas.

Methods

Here, we profiled over 69 metabolites in 17 patient-derived xenografts by targeted mass spectrometry to determine if metabolomic differences exist in mutant IDH1, mutant IDH2, and non-mutant chondrosarcomas. UMAP (Uniform Manifold Approximation and Projection) analysis was performed on our dataset to examine potential similarities that may exist between each chondrosarcoma based on genotype.

Results

UMAP revealed that mutant IDH chondrosarcomas possess a distinct metabolic profile compared with non-mutant chondrosarcomas. More specifically, our targeted metabolomics study revealed large-scale differences in organic acid intermediates of the tricarboxylic acid (TCA) cycle, amino acids, and specific acylcarnitines in chondrosarcomas. Lactate and late TCA cycle intermediates were elevated in mutant IDH chondrosarcomas, suggestive of increased glycolytic metabolism and possible anaplerotic influx to the TCA cycle. A broad elevation of amino acids was found in mutant IDH chondrosarcomas. A few acylcarnitines of varying carbon chain lengths were also elevated in mutant IDH chondrosarcomas, but with minimal clustering in accordance with tumor genotype. Analysis of previously published gene expression profiling revealed increased expression of several metabolism genes in mutant IDH chondrosarcomas, which also correlated to patient survival.

Conclusions

Overall, our findings suggest that IDH mutations induce global metabolic changes in chondrosarcomas and shed light on deranged metabolic pathways.

Full Text

Duke Authors

Cited Authors

  • Pathmanapan, S; Ilkayeva, O; Martin, JT; Loe, AKH; Zhang, H; Zhang, G-F; Newgard, CB; Wunder, JS; Alman, BA

Published Date

  • March 24, 2021

Published In

Volume / Issue

  • 9 / 1

Start / End Page

  • 13 -

PubMed ID

  • 33762012

Pubmed Central ID

  • PMC7992867

Electronic International Standard Serial Number (EISSN)

  • 2049-3002

International Standard Serial Number (ISSN)

  • 2049-3002

Digital Object Identifier (DOI)

  • 10.1186/s40170-021-00247-8

Language

  • eng